成人无码高潮av在线观看_欧洲极品少妇_夂久亚州精华国产精华华液_在线观看亚洲AV每日更新无码_亚洲国产精品无码久久一线_亚洲精品区午夜亚洲精品区

加拿大Axcan Pharma Inc. 
Axcan Pharma Inc. (圣海拉爾山， Mont Saint Hilaire) 宣布在北美的ITAX (itopride)第三期臨床測試病人登錄，其亂度規(guī)劃己超越預(yù)計(jì)之500人目標(biāo)設(shè)計(jì)。額外的登記人數(shù)尚在篩檢過程，公司預(yù)定會(huì)持續(xù)進(jìn)行臨床測試的亂度規(guī)劃設(shè)計(jì)至2005年12月底，以符合原訂進(jìn)度。事實(shí)上如公司在2005年11月10日所宣布的，參與國際臨床測試所需的病人數(shù)目，已完成納入亂度規(guī)劃進(jìn)度。這項(xiàng)臨床藥物發(fā)展計(jì)劃包括兩個(gè)第三期臨床測試，一個(gè)是在北美，另一個(gè)就是國際臨床測試。這項(xiàng)計(jì)劃的目的在于測試Itopride藥物在治療一種胃腸性疾病，也就是功能性消化不良(Functional Dyspepsia)時(shí)的安全性及有效性。Axcan公司希望能夠在2006年的前半年可以宣告這項(xiàng)北美第三期臨床測試大體結(jié)果。臨床測試成果細(xì)節(jié)則較可能會(huì)在一個(gè)國際胃腸性疾病學(xué)術(shù)研討會(huì)中發(fā)表。
Axcan Pharma is a privately-held, leading specialty pharmaceutical company that develops and markets a wide range of products to treat gastrointestinal diseases and disorders, such as inflammatory bowel disease, cholestatic liver diseases, irritable bowel syndrome, and complications related to pancreatic insufficiency. All Axcan’s activities underscore the Company's single, well-defined Mission - to improve the quality of care and health of patients suffering from gastrointestinal diseases and disorders by providing effective therapies for patients and their specialized caregivers.

Through internal product development and synergistic acquisitions of products and companies, Axcan has built a leadership position in the North American gastroenterology market; just under 85 percent of the Company's business is generated from North American sales. Since Axcan markets its specialized products to a relatively cohesive community of physicians, its sales forces are able to reach this market more easily than pharmaceutical companies with a product portfolio targeting a more diverse range of diseases. Axcan's products are marketed by its own dedicated and specialized sales forces both in North America and the European Union.

Axcan Pharma and its global operations are working hand-in-hand to become a multinational leader for disorders linked to gastroenterology. Currently, the Company markets more than 40 products and dosage strengths worldwide in the field of gastroenterology, including several that hold a leading market position.

In addition to its marketing activities, Axcan carries out research and development of products at an advanced stage of development that it acquires or licenses from third parties. By combining its marketing expertise with its research and development experience, Axcan distinguishes itself from specialty pharmaceutical companies that focus solely on the distribution of products and offers potential licensors the prospect of rapidly expanding the market for their products.

Axcan’s unique expertise in its field, combined with its excellent industry reputation and international reach, has enabled the Company to maintain its consistent growth trend and attain its strong market position. Axcan’s solid and stable base business provides a platform for the Company to capitalize on its proven business strategy, in order to continue to achieve significant future growth.

The Company plans to continue to grow its business by:

increasing market penetration and sales of existing products;
developing and obtaining marketing approval for new products;
in-licensing products and acquiring new products or companies;
development of its research and development portfolio, and
expanding geographically.
Axcan’s corporate headquarters are based outside of Montreal, Quebec, Canada. The Company employs almost 500 people worldwide and has additional offices in both the United States and France.